CHRISANNA DOBROWOLSKI

Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology BRONX, NY NPI 1639619729

General Payments — all program years on this page

$1,222.58

  • Category: General Payments
  • Program years: PY2023–2024
  • Record count: 18
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $1,145.68 across 15 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $681.623
Acerta Pharma LLC $342.556
GlaxoSmithKline, LLC. $73.154
NOVARTIS PHARMACEUTICALS CORPORATION $28.861
Amgen Inc. $19.501

By program year

Program yearAmountRecords
2023 $76.903
2024 $1,145.6815

Records — PY2024 (15)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1086960915 Novartis Pharmaceuticals Corporation $28.86 04/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101303857 E.R. Squibb & Sons, L.L.C. $30.20 07/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101303859 E.R. Squibb & Sons, L.L.C. $325.71 03/04/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1101303949 E.R. Squibb & Sons, L.L.C. $325.71 03/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1104304124 AstraZeneca Pharmaceuticals LP $123.73 10/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104607420 AstraZeneca Pharmaceuticals LP $22.40 10/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104622830 AstraZeneca Pharmaceuticals LP $30.17 06/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105503426 AstraZeneca Pharmaceuticals LP $30.63 03/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105548237 AstraZeneca Pharmaceuticals LP $125.00 02/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105566688 AstraZeneca Pharmaceuticals LP $10.62 03/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116175783 GlaxoSmithKline, LLC. $15.12 04/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116203120 GlaxoSmithKline, LLC. $24.89 05/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116397134 GlaxoSmithKline, LLC. $16.10 05/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116456403 GlaxoSmithKline, LLC. $17.04 07/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117240256 Amgen Inc. $19.50 03/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.